Switch to:
GuruFocus has detected 1 Warning Sign with Cascadian Therapeutics Inc $CASC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
Cascadian Therapeutics Inc (NAS:CASC)
Additional Paid-In Capital
$386.67 Mil (As of Mar. 2017)

Cascadian Therapeutics Inc's quarterly additional paid-in capital increased from Sep. 2016 ($297.32 Mil) to Dec. 2016 ($297.92 Mil) and increased from Dec. 2016 ($297.92 Mil) to Mar. 2017 ($386.67 Mil).

Cascadian Therapeutics Inc's annual additional paid-in capital increased from Dec. 2014 ($224.55 Mil) to Dec. 2015 ($249.57 Mil) and increased from Dec. 2015 ($249.57 Mil) to Dec. 2016 ($297.92 Mil).


Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)*Shares Outstanding

Related Terms

Shares Outstanding

Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Cascadian Therapeutics Inc Annual Data

AdditionalPaidInCapital 13.6415.0916.2917.3374.54126.83154.83224.55249.57297.92

Cascadian Therapeutics Inc Quarterly Data

AdditionalPaidInCapital 224.55247.47248.20248.74249.57252.47296.53297.32297.92386.67
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat